Dysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to promote survival following inhibition of the kinase EGFR, even in cells that are not ‘addicted’ to EGFR signaling.
This is a preview of subscription content, log in via an institution to check access.
References
Zhang, Y. L. et al. Oncotarget 7, 78985–78993 (2016).
Yu, H. A. et al. Clin. Cancer Res. 19, 2240–2247 (2013).
Soria, J. C. et al. N. Engl. J. Med. 378, 113–125 (2018).
Piotrowska, Z. et al. Cancer Discov. 8, 1529–1539 (2018).
Le, X. et al. Clin. Cancer Res. 24, 6195–6203 (2018).
Sequist, L.V. et al. Lancet Oncol. 21, 373–386 (2020).
Lee, H. J. et al. Cancer Cell 26, 207–221 (2014).
Blakely, C. M. et al. Cell Reports 11, 98–110 (2015).
Terai, H. et al. Cancer Res. 78, 1044–1057 (2018).
Gong, K. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-0048-0 (2020).
Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cancer Cell 34, 361–378 (2018).
Ivashkiv, L. B. & Donlin, L. T. Nat. Rev. Immunol. 14, 36–49 (2014).
Barbie, D. A. et al. Nature 462, 108–112 (2009).
Gainor, J. F. et al. Clin. Cancer Res. 22, 4585–4593 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Yoshida, R., Barbie, D.A. EGFR blockade activates interferon. Nat Cancer 1, 376–378 (2020). https://doi.org/10.1038/s43018-020-0055-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-0055-1
- Springer Nature America, Inc.